Skip to main content
Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice
Surgery Publications and Presentations
  • Jennifer F. Tseng, University of Massachusetts Medical School
  • Filip A. Farnebo, Harvard Medical School
  • Oliver Kisker, Harvard Medical School
  • Christian M. Becker, Harvard Medical School
  • Calvin J. Kuo, Harvard Medical School
  • Judah Folkman, Harvard Medical School
  • Richard C. Mulligan, Harvard Medical School
UMMS Affiliation
Department of Surgery
Publication Date
Document Type
Adenocarcinoma; Adenoviridae; Animals; Cell Division; Female; *Gene Transfer Techniques; Genetic Vectors; Humans; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pancreatic Neoplasms; Solubility; Splenic Neoplasms; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2
BACKGROUND: Because pancreatic adenocarcinoma is poorly responsive to chemotherapy and radiation therapy, novel treatments such as antiangiogenic gene therapy may have use in the adjuvant treatment of this malignancy. We evaluated the antitumor effects of the in vivo administration of an adenovirus vector encoding a soluble form of Flk1 (Flk1-Fc), a receptor for vascular endothelial growth factor, in 3 murine models of pancreatic adenocarcinoma. METHODS: In a first model, immunocompetent C57Bl/6 mice were injected subcutaneously with Panc02 murine pancreatic adenocarcinoma cells before treatment. In a second model, immunodeficient severe combined immunodeficiency mice were injected subcutaneously with BxPc-3 human pancreatic adenocarcinoma cells before treatment. In a third model, C57Bl/6 mice were injected with Panc02 cells through an intrasplenic route before treatment, in an effort to model metastatic disease. In each model, half the tumor-bearing mice were injected intravenously with 10(9) Flk1-Fc adenovirus particles and half with control adenovirus. RESULTS: In subcutaneous tumor models, Ad Flk1-Fc-treated animals were found to have 75% smaller murine and 78% smaller human pancreatic tumor volumes, relative to tumor volumes of Ad Fc-treated animals, 6 weeks after vector administration. In animals injected with tumor through the intrasplenic route, pathologic and histologic analyses made 10 days after injection of tumor revealed hepatic, pancreatic, and splenic tumors, together with a desmoplastic response consistent with pathologic findings in human pancreatic cancer. Cohorts of these tumor-bearing mice treated with Ad Flk1-Fc demonstrated significantly longer survival and decreased liver replacement with tumor at the time of death, relative to animals treated with Ad Fc. CONCLUSION: A recombinant adenovirus encoding soluble Flk-1 inhibited pancreatic tumor growth in mice. These studies suggest that the delivery of gene products such as Flk1-Fc through in vivo gene transfer may be useful in the future treatment of patients with pancreatic cancer.
DOI of Published Version
Surgery. 2002 Nov;132(5):857-65. Link to article on publisher's site

At the time of publication, Jennifer Tseng was not yet affiliated with the University of Massachusetts Medical School.

Related Resources
Link to Article in PubMed
PubMed ID
Citation Information
Jennifer F. Tseng, Filip A. Farnebo, Oliver Kisker, Christian M. Becker, et al.. "Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice" Vol. 132 Iss. 5 (2002) ISSN: 0039-6060 (Linking)
Available at: